Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MedImmune To Continue FluMist Development; Wyeth Remains Undecided

Executive Summary

MedImmune is confident it can successfully develop FluMist on its own should Wyeth decide to back out of the companies' partnership for the intranasal flu vaccine

You may also be interested in...



MedImmune Gets Back FluMist: Physicians Will Be Focus Post-Wyeth

MedImmune is getting "back to basics" on FluMist promotional efforts with a focus on physician education now that the company has regained sole rights to the intranasal flu vaccine from Wyeth

MedImmune Gets Back FluMist: Physicians Will Be Focus Post-Wyeth

MedImmune is getting "back to basics" on FluMist promotional efforts with a focus on physician education now that the company has regained sole rights to the intranasal flu vaccine from Wyeth

FluMist Price Likely To Be Cut To $20-$25 Per Dose, MedImmune Says

MedImmune is considering reducing the price for the intranasal flu vaccine FluMist to $20-$25 per dose for the 2004-2005 season, CEO David Mott indicated during a first quarter conference call April 21

Related Content

UsernamePublicRestriction

Register

MT101489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel